Treat CHB! AXA Pharmaceuticals APG-1387 Phase II Clinical Completion of First Patient Administration

The study is an international multi-center, open Phase II clinical study designed to assess the efficacy and safety of APG-1387 joint ntikavir spent in patients with primary or chronic hepatitis B treatment, and to plan for a total of 104 patients in a global group of 104 patientsAccording to the World Health Organization (WHO) 2017 report, there are about 257 million people infected with chronic hepatitis B virus (HBV) worldwide, and about 650,000 people die each year from liver failure, cirrhosis and hepatocellular carcinoma caused by HBV infectionThe standard anti-HBV treatments recommended by major global guidelines include enticave, tinofovir, phospial provove and long-acting interferonBut the long-term treatment of these drugs only allows a small number of patients to obtain hBsAg surface antigen (HBsAg) vulva, as well as a continuous immune response after discontinuationMost patients still need long-term or even life-long medicationTherefore, obtaining safe and effective drugs to cure hepatitis B within a limited course of treatment, minimizing the risk of disease progression, remains a huge and unmet clinical needAPG-1387 is a new generation of apoptosis protein inhibitors (IAP) high-efficiency-specific inhibitors in aerateing pharmaceutical research, mainly by simulating endogenous SMAC molecular degradation iAPs to induce and accelerate the process of apoptosisDuring chronic HBV infection, HBV itself or inflammatory factors may inhibit the apoptosis effect of cell immunity-mediated cell by promoting the expression of cIAPs molecules in the liver cells, promote the survival of infected liver cells, and cause the infection to persistAt the same time, the inhibitory and elimination effect of APG-1387 on chronic HBV infection in different models was confirmed in in vivo and external experimentsAPG-1387 is the first IAP inhibitor in China to enter the clinical phase(Original text)References1, Global Hepatitis Report 2017.
Ebert G., et al., cellular put of apoptos protein s oede of hepatitis B virusProc Natl Acad Sci, 2015.112 (18): p5797-5802